RxTally.CA — Canadian maple leaf logoClarity in every comparison.
Research · Canada

Generic semaglutide changed the coverage math. Here's the number to watch.

A McGill study found that at generic prices, the diabetes treatment that guidelines already recommend becomes more affordable to cover — and one price point would settle the argument.

By RxTallyLast Update 3 min read

The short version

At brand prices, the math didn't work. In February 2026, McGill researchers estimated that GLP-1 drugs like semaglutide were not cost-effective for type 2 diabetes patients at high heart and kidney risk, compared with cheaper SGLT2 inhibitors — using 2025 prices reimbursed by Quebec's public drug plan.

At generic prices, it does. Generic semaglutide is now available through Quebec's public plan at about $1,060 a year, dispensing fees included. At that price, the researchers estimate a 35% probability that combination therapy — a GLP-1 drug plus an SGLT2 inhibitor — is the most cost-effective strategy, versus either drug alone.

The number to watch is $880. If the annual price falls to $880, the probability that combination therapy beats SGLT2 inhibitors alone rises to 80%. That is the threshold at which the coverage argument stops being close.

Why this study matters for coverage

The study, published in the Canadian Journal of Cardiology and led by researchers at McGill University and the Research Institute of the McGill University Health Centre, looked at up to 2.1 million Canadians living with type 2 diabetes and high cardiovascular risk — the group guidelines say should be getting these drugs.

At 2025 brand-name prices, covering all of them with GLP-1 therapy would cost an estimated $3.35 billion to $5.31 billion a year. The authors expect generic pricing to cut that by at least half. That is the scale of the change: not a discount, but a different budget conversation — and the researchers say the findings strengthen the case for broader coverage through public and private drug plans.

Canada got here first. The country is one of the first in the world to have generic semaglutide, years before it is expected in the United States and much of Europe. That head start is why the coverage question is live here now, and not elsewhere.

Five generics now, not three

The study was written when three generic semaglutide products had been approved. As of October 2026 there are five: Dr. Reddy's (April 28), Apo-Semaglutide (May 1), Sevmia (June 29), Aspen-Semaglutide (July 21), and Sandoz (September 18). Prices are expected to keep falling as more manufacturers enter — which is exactly the direction the $880 threshold points. Track the list on our generic semaglutide tracker.

For context on the study's Quebec figure: $1,060 a year works out to roughly $82 per four-week pen, dispensing fees included — a public-plan reimbursed price, below the $88–$103 a pen our tracker sees at retail pharmacies. The two numbers describe different prices for the same drug, not a contradiction.

What the study doesn't say

This is a simulation, not a clinical trial — the 35% and 80% figures are model probabilities, not guarantees. The $1,060 price is specific to Quebec's public plan. And the analysis does not consider weight-loss use at all: it says nothing about whether Wegovy or any drug should be covered for obesity. Don't stretch it there.

What to do with this

  • If you have type 2 diabetes and a public plan: generic semaglutide is already listed for diabetes in Ontario, Alberta, Saskatchewan and Manitoba, and under review or listed elsewhere — check your province's formulary. See our Ozempic coverage guide.
  • If you're paying out of pocket: the generic is the cheapest route to semaglutide in Canada, and the price is still falling. Our total-cost calculator models the generic option.
  • If you're watching the coverage debate: $880 a year is the number. When a public plan can buy a year of semaglutide for that, the cost-effectiveness case for covering combination therapy becomes hard to argue against — and that is the number that will show up in the next round of formulary decisions.

Sources

McGill University Health Centre — "Generic semaglutide could reshape diabetes drug coverage in Canada," August 19, 2026 · McNally E, Sharma A, Marques P, Tsoukas MA, Mavrakanas T, Russell WA — "Implications of Generic Semaglutide Availability on the Cost-Effectiveness of GLP-1RA for Guideline-Indicated Patients With Type 2 Diabetes," Canadian Journal of Cardiology (Elsevier); supported by Mitacs and the MUHC Foundation · Generic authorization dates: Dr. Reddy's April 28, 2026; Apo-Semaglutide May 1, 2026; Sevmia June 29, 2026; Aspen-Semaglutide July 21, 2026; Sandoz September 18, 2026 (Health Canada). The $82-per-pen figure is RxTally's arithmetic ($1,060 ÷ 13 four-week fills), not a quoted price.

This article explains coverage research; it is not medical advice and does not determine your benefits. Formulary listings and plan rules change — confirm your own coverage with your provincial program and insurer before filling a prescription. Medical disclaimer · Methodology